Search

Displaying results 3611 - 3620 of 7540 in total
  1. Drug

    Influenza A virus A/Brisbane/10/2010 live (attenuated) antigen

    go.drugbank.com/drugs/DB16517
    Approved

    Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … that it was previously exposed to.

  2. Drug

    Influenza A virus A/South Australia/55/2014 live (attenuated) antigen

    go.drugbank.com/drugs/DB16518
    Approved

    Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … that it was previously exposed to.

  3. Drug

    Influenza A virus A/Tasmania/503/2020 (H3N2) live (attenuated) antigen

    go.drugbank.com/drugs/DB16718
    Approved

    Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … that it was previously exposed to.

  4. Drug

    Influenza A virus A/Victoria/2570/2019 IVR-215 (H1N1) antigen (UV, formaldehyde inactivated)

    go.drugbank.com/drugs/DB16720
    ApprovedWithdrawn

    Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … that it was previously exposed to.

  5. Drug

    Influenza A virus A/Victoria/2570/2019 IVR-215 (H1N1) antigen (propiolactone inactivated)

    go.drugbank.com/drugs/DB16722
    ApprovedWithdrawn

    Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … that it was previously exposed to.

  6. Drug

    Influenza A virus A/Brisbane/02/2018 IVR-190 (H1N1) antigen (propiolactone inactivated)

    go.drugbank.com/drugs/DB15500
    ApprovedWithdrawn

    Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … that it was previously exposed to.

  7. Drug

    Influenza B virus B/Iowa/06/2017 antigen (MDCK cell derived, propiolactone inactivated)

    go.drugbank.com/drugs/DB15508
    ApprovedWithdrawn

    Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … that it was previously exposed to.

  8. Drug

    Influenza A virus A/Brisbane/02/2018 IVR-190 (H1N1) antigen (UV, formaldehyde inactivated)

    go.drugbank.com/drugs/DB15519
    ApprovedWithdrawn

    Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … that it was previously exposed to.

  9. Drug

    Influenza B virus B/Singapore/INFTT-16-0610/2016 hemagglutinin antigen (MDCK cell derived, propiolactone inactivated)

    go.drugbank.com/drugs/DB15564
    Approved

    Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … that it was previously exposed to.

  10. Drug

    Etesevimab

    go.drugbank.com/drugs/DB15897
    Investigational

    progressing to severe COVID-19:[L40179] this EUA later expanded in December 2021 to include all younger children at high risk, including newborns. … [L16651,L16661] Under the EUA granted in February 2021, etesevimab is used in combination with [bamlanivimab] to treat mild to moderate COVID-19 in adults and pediatric patients who are at high risk for